3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Neoplasms
27
Colorectal Neoplasms
20
Breast Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
13
Neoplasm Metastasis
12
Lung Neoplasms
11
Stomach Neoplasms
10
Leukemia, Myeloid, Acute
10
Melanoma
9
Lymphoma, Non-Hodgkin
8
Small Cell Lung Carcinoma
6
Recurrence
6
Liver Neoplasms
6
Leukemia
6
Head and Neck Neoplasms
6
Fallopian Tube Neoplasms
6
Prostatic Neoplasms
5
Glioblastoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Gastrointestinal Neoplasms
4
Uterine Cervical Neoplasms
3
Interventions
Fluorouracil
3
irinotecan sucrosofate
2
Leucovorin
2
zolbetuximab
1
pembrolizumab
1
beta-D-glucosylisophosphoramide mustard
1
Drug Therapy
1
4-fluorobenzoyl-TN-14003
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Pancreatic Adenocarcinoma
×
Drug Therapy
×
Clear all
NCT02826486
2024-08-28
COMBAT
BioLineRx, Ltd.
Phase 2
Completed
80 enrolled
13 charts